Constant Therapeutics

Executive Summary

Constant Therapeutics is a private clinical-stage biopharmaceutical company developing Mas receptor agonists for COVID-19, CNS, and rare disorders. Its lead candidate, talfirastide (TXA127), is a pharmaceutical formulation of angiotensin 1-7 that activates the protective arm of the renin-angiotensin system, offering anti-inflammatory and anti-fibrotic effects. The company has advanced talfirastide into multiple Phase 2 trials: a completed trial in COVID-19 (NCT04401423) showed favorable signals, and ongoing trials are evaluating it in DMD-associated dilated cardiomyopathy (NCT06013839) and ischemic stroke (NCT06135103). Despite a history of terminated earlier trials, the platform has potential for multiple indications. Constant's focus on novel mechanisms and rare diseases positions it for potential value inflection as clinical data mature, though the private status and limited public information add uncertainty.

Upcoming Catalysts (preview)

• H2 2026Phase 2 topline data for talfirastide in ischemic stroke50% success
• 2026Phase 2 interim or final data for talfirastide in DMD-associated dilated cardiomyopathy40% success
• TBDPotential partnering or licensing deal for talfirastide in COVID-19 or CNS indications30% success